ESPAD Survey: Vaping Prevalent among European Students

Sep.01.2022
ESPAD Survey: Vaping Prevalent among European Students
The ESPAD project investigates alcohol, tobacco, and drug use among 15-16 year old students in 35 European countries.

The European School Survey Project on Alcohol and Other Drugs (ESPAD) is the largest survey of alcohol, tobacco, and illegal drug use among 15-16 year old students in 35 European countries. It is coordinated by the Institute of Clinical Physiology of the National Research Council of Italy (CNR-Ifc). Using standardized methods since 1999, this survey is able to assess changes in young people's habits and has recently garnered interest from the World Health Organization.


Data shows that traditional tobacco cigarette use is declining among adolescents, possibly due to prevention and comparison policies implemented in many countries. However, concerning data about electronic cigarette use has emerged as a worrying trend. In response, the epidemiology and health services research department of CNR-Ifc conducted a study titled "Electronic Cigarette Use and Conventional Smoking Among European Students: Results From the 2019 ESPAD Survey," published in the journal Addiction, to analyze how tobacco control policies impact these habits.


In 2019, a study of approximately 100,000 ESPAD students found that 40.6% had tried traditional cigarettes at least once, with 19.3% currently being smokers. The percentage of smokers varied from 5.1% in Iceland to 32.4% in Italy. On the other hand, 37.8% of students reported trying e-cigarettes, with 12.4% currently using them (13.4% in Italy). According to the study's author, Sonia Cerrai, it can be assumed that young people's attitudes towards new smoking habits will continue to grow, due to the ease of access and perception of low risk.


In the ten countries analyzed, the use of electronic cigarettes has surpassed traditional smoking," stated Cerrai. "While electronic cigarettes may not necessarily contain nicotine, these tech products that are highly attractive to young people and very young individuals are frequently used in conjunction with traditional cigarettes, with usage ranging from 2% in Cyprus to 15% in Monaco (8.9% in Italy) within the sample.


However, implementing tobacco control policies by the government can also contribute to preventing smoking. "In this analysis, we used the Tobacco Control Scale index, which scores policies based on the measures taken," explained Cerrai. "We also considered some specific factors in our analysis: price increases showed a clear association with decreased use of two smoking methods. More spending on information campaigns and cessation programs only correlated with traditional smoking, while measures to prohibit the promotion and advertising of electronic devices were stricter.


According to researchers, the marketing for new devices emphasizes safety by reducing the risks associated with tobacco smoke exposure. However, this complete change in consumption patterns could lead to distractions for young people, who are also familiar with prevention initiatives and programs implemented in the past 20 years.


Statement: 1. The content of this article is compiled from third-party information, provided solely for industry exchange and learning purposes. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The compilation of this article is only for industry exchange and research purposes. 3. Due to limitations in the compilation process, the compiled article may not fully match the original text. Please refer to the original text for accuracy. 4. 2FIRSTS fully aligns with the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign issues. 5. Copyright for compiled information belongs to the original media and author. Please contact us for removal if there is any infringement.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
RELX and UK e-liquid brand T-Juice have launched the Prime Pro × Red Astaire bundle in France, combining the RELX Prime Pro open-system pod device with T-Juice’s signature Red Astaire nicotine salt e-liquid. The collaboration retains the existing Prime Pro hardware platform while using an established flavor brand to create a complete open-system offering. The product appeared in French retail and distribution channels in August 2026 and represents a co-branded retail bundle rather than a new device launch.
Aug.27
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
SMOORE’s DOJO by VAPORESSO to Launch New Global Brand Identity on September 1
SMOORE’s DOJO by VAPORESSO to Launch New Global Brand Identity on September 1
According to recent LinkedIn posts from people at VAPORESSO, SMOORE and a German distribution partner, vape brand DOJO will begin rolling out a new global brand identity on September 1, 2026, led by a redesigned handwritten logo. The new visual system will be gradually applied across product packaging, marketing materials and digital assets over the following months. Fabio Corsaro, Head of Marketing and Purchasing at MG Wesel GmbH, said the rebrand was related to trademark issues, but that explanation has not been publicly confirmed by DOJO, VAPORESSO or SMOORE. DOJO is currently promoting its Blast X product in Germany.
Aug.31
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08